(AOF) – Intrasense, a company that develops and markets Myrian, a software platform facilitating and securing diagnosis, decision-making and therapeutic monitoring, has published a net loss of 1.94 million euros in the first half, compared with – 664,000 euros, a year earlier. Its Ebitda shows a loss of 991,000 euros against -470,000 euros a year earlier. Although the gross margin improved by 18.2% to 1.71 million and the turnover increased by 5.3% to 1.90 million, the company’s results therefore remain in the red in the first half. 2022.
The company explains in its press release that its losses are linked to its investment policy decided in mid-2021 and that it is managed in a monitored and controlled manner.
The recruitment of new Marketing and R&D talents, dedicated to the development of the new oncology product line and the integration of artificial intelligence within Myrian – with new partnerships concluded with Milvue and Nurea this semester – constitutes a sustainable lever innovation and growth for the group.
The strengthening of the sales team in China and France is bringing very encouraging initial results, in the context of a Chinese market tempted by the protectionist regime and despite the geopolitical difficulties in Ukraine.
2022 is a pivotal year following the capital increase carried out in June 2021.
The prototype of the new range of oncology products will be tested from the end of 2022, within the framework of several strong partnerships with major players in the world of cancer treatment. This next step will make it possible to prepare for the marketing of the product in 2023.
Concerning Myrian, new artificial intelligence clinical functionalities will enrich its offer, with the integration of new algorithms. The Group will also gradually develop the economic model of its radiology platform over the coming years, within the framework of major technological developments, thus allowing the development of stronger recurring revenues, subscription offers and services. .
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.